Ultra-low dose estradiol plus dydrogesterone: a role in prevention of the development and progression of atherosclerosis
- Authors: Kryukov E.V.1,2, Popova L.V.3,4, Vasiliev S.V.3, Panevin T.S.1, Panevina A.S.3, Stromskaya U.A.3, Samoilova N.V.3, Makarov O.E.3
-
Affiliations:
- Chief Military Clinical Hospital named after N.N. Burdenko
- Military Medical Academy named after S.M. Kirov
- All-Russian Association for the Study of Thrombosis, Hemorrhagia and Vascular Pathology named after A.A. Schmidt and B.A. Kudryashov
- The First Moscow State Medical University named after I.M. Sechenov
- Issue: Vol 23, No 1 (2021)
- Pages: 9-14
- Section: Clinical trials
- URL: https://journals.rcsi.science/1682-7392/article/view/63562
- DOI: https://doi.org/10.17816/brmma63562
- ID: 63562
Cite item
Abstract
Active development of the "anti-aging medicine", attempts to slow down biological (including vascular) aging led to the creation of new pharmaceuticals including menopausal hormone therapy. The vascular wall protective mechanism of the hormones is not completely clear, but it was shown that natural estrogens are able to control the condition of the vascular wall, prevent platelet adhesion, control a range of metabolic and trophic and energy processes in the endothelium of the vascular wall, producing antithrombogenic factors, namely their inhibition contributes to the development of atherosclerosis. It is known that standard and low-dose estrogen may restore the impaired antithrombogenic potential of the vascular wall, provided its initial reduction does not exceed 20%. The issue of the role and possibilities of correction of the antithrombogenic activity of the vascular wall with ultra-low dose estradiol remained unresolved. As a "clinical model" for the study of this issue, we formed 2 groups of patients: in the study group patients received ultra-low dose estradiol plus dydrogesterone, subjects from the control group received beta-alanine. Three-year follow-up showed a decrease in antithrombogenic activity of the vascular wall in control subjects after 2 and 3 years of follow-up according to the M.V. Baluda's test versus subjects treated with ultra-low dose estrogen plus dydrogesterone. The decrease of the relative risk of reduction of the antithrombogenic activity of the vascular wall with the use of ultra-low dose estrogen plus dydrogesterone during the first two years was 2.3 times, and during the 3 years of follow-up — 3.8 times versus control. Thus, prescribing only ultra-low dose estradiol plus dydrogesterone for patients with normal antithrombogenic activity of the vessel wall at baseline reliably lowers the risk of long-term reduction of antithrombogenic potential of the vascular wall.
Full Text
##article.viewOnOriginalSite##About the authors
Evgeniy V. Kryukov
Chief Military Clinical Hospital named after N.N. Burdenko; Military Medical Academy named after S.M. Kirov
Author for correspondence.
Email: evgeniy.md@mail.ru
ORCID iD: 0000-0002-8531-0205
SPIN-code: 3900-3441
Scopus Author ID: 57208311867
MD, PhD, Professor
Russian Federation, Moscow; Saint PetersburgLyudmila V. Popova
All-Russian Association for the Study of Thrombosis, Hemorrhagia and Vascular Pathology named after A.A. Schmidt and B.A. Kudryashov; The First Moscow State Medical University named after I.M. Sechenov
Email: mila_foka@mail.ru
ORCID iD: 0000-0002-3496-6466
Сandidate of medical sciences
Russian Federation, Moscow; MoscowSergey V. Vasiliev
All-Russian Association for the Study of Thrombosis, Hemorrhagia and Vascular Pathology named after A.A. Schmidt and B.A. Kudryashov
Email: vasilivsenator@gmail.com
ORCID iD: 0000-0002-3485-4050
SPIN-code: 4831-6263
Doctor of mathematical sciences, professor
Russian Federation, MoscowTaras S. Panevin
Chief Military Clinical Hospital named after N.N. Burdenko
Email: tarasel@list.ru
ORCID iD: 0000-0002-5290-156X
SPIN-code: 7839-3145
Endocrinologist
Russian Federation, MoscowAnna S. Panevina
All-Russian Association for the Study of Thrombosis, Hemorrhagia and Vascular Pathology named after A.A. Schmidt and B.A. Kudryashov
Email: annapv3010@gmail.com
ORCID iD: 0000-0003-2744-7550
Сandidate of medical sciences
Russian Federation, MoscowUlyana Andreevna Stromskaya
All-Russian Association for the Study of Thrombosis, Hemorrhagia and Vascular Pathology named after A.A. Schmidt and B.A. Kudryashov
Email: yavisya@list.ru
ORCID iD: 0000-0002-4040-9658
SPIN-code: 1329-4060
Russian Federation, Moscow
Natalia V. Samoilova
All-Russian Association for the Study of Thrombosis, Hemorrhagia and Vascular Pathology named after A.A. Schmidt and B.A. Kudryashov
Email: nsamoylova2@yandex.ru
Сandidate of medical sciences
Russian Federation, MoscowOleg E. Makarov
All-Russian Association for the Study of Thrombosis, Hemorrhagia and Vascular Pathology named after A.A. Schmidt and B.A. Kudryashov
Email: Lioton@yandex.ru
Сandidate for a degree
Russian Federation, MoscowReferences
- Potter B. Menopause. P. Care. 2018;4:625–641.
- Kryukov EV, Panevin TS. Antitrombogenic vascular wall activity in women with climacteric myocardiodystrophy while menopause. Bulletin of Pirogov National Medical and Surgical Center. 2020;15(2):67–70. (In Russ.)
- Tapilskaya NI, Glushakov RI. Principally, my friends, may brains not to get old. Potential of menopausal hormone therapy in brain aging prevention. StatusPraesens. Gynecology, obstetrics, infertility. 2019;(4):74–78. (In Russ.)
- Chester RC, Kling DM, Manson DI. What the Women's Health Initiative has taught us about menopausal hormone therapy. Clin Cardiol. 2018;41(2):247–252. doi: https://doi.org/10.1002/clc.22891
- Piróg M Jach R, Kacalska-Janssen O. Differential effect of the ultra-low dose and standard estrogen plus dydrogesterone therapy on thrombin generation and fibrinolysis in postmenopausal women. Acta Obstet Gynecol Scand. 2017;96(12):1438–1445.
- Pinkerton JV, James AH. Management of Menopausal Symptoms for Women Who Are at High Risk of Thrombosis. Clin Obstet Gynecol. 2018;61(2):260–268. doi: https://doi.org/10.1097/GRF.0000000000000358
- Godo S, Shimokawa H. Endothelial functions Arterioscler Thromb. Vasc Biol. 2017;(37):108–114.
- Kryukov EV, Panevin TS, Popova LV. Aging of hemostasis. Clinical Medicine. 2020;98(1):9–12. (In Russ.)
- Konukoglu D, Uzun H. Endothelial Dysfunction and Hypertension Adv Exp Med Biol. 2017;(956):511–540.
- Baluda VP, Baluda MV, Deyanov II, et al. Physiology of hemostasis: study guide. Moscow, 1995. (In Russ.)
- Panevina AS, et al. Alterations of proinflamatory cytokines and antitrombogenic vascular wall activity in case of menopausal hormone therapy use. Clinical medicine. 2018;96(11):1029–1033. (In Russ.)
- Dinger J, Bardenheuer K, Heinemann K. Drospirenone plus estradiol and the risk of serious cardiovascular events in postmenopausal women. Climacteric. 2016;19(4):349–356.
- Ivanova OY, Tugarinova MS, Maltseva NV, Timofeenko AI. Clinical case of pregnancy complicated by cardiomyopathy. StatusPraesens. Gynecology, obstetrics, infertility. 2020;(2/3)[65/67]:143–145. (In Russ.)
- Maisch B, Volker R. Cardiomyopathies: classification, diagnosis, and treatment. Heart Fail Clin. 2012;8(1):53–78.
- Yarmolinskaya MI, Makletsova SA, Ipastova ID. Comdined estrogen and gestogen contraceptives and thrombosis: view of actualist. StatusPraesens. Gynecology, obstetrics, infertility. 2017;38(2):69–78. (In Russ.)